Skip to main content

Advertisement

Table 2 Synergistic combinations of targeted drugs in glioma tumor-initiating cells

From: Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells

Drugs GSC11 GSC47 GSC20 GSC2
Erlotinib + Sorafenib 0.85 ± 0.23 1.30 ± 0.16 1.21 ± 0.26 1.04 ± 0.24
Lapatinib + Sorafenib 0.82 ± 0.27 1.17 ± 0.40 1.18 ± 0.05 1.32 ± 0.06
Erlotinib + U0126 0.98 ± 0.24 2.14 ± 0.75 0.73 ± 0.08 0.52 ± 0.31
Erlotinib + PD98059 NE NE 0.79 ± 0.17 NE
Lapatinib + U0126 NE NE 0.86 ± 0.12 NE
Erlotinib + BKM120 1.16 ± 0.19 NE 1.04 ± 0.24 0.71 ± 0.05
Sorafenib + U0126 0.67 ± 0.13 0.73 ± 0.09 1.20 ± 0.59 0.56 ± 0.30
  1. Chou and Talalay combination indices (CI) are shown as means ± 95 % confidence intervals of at least two independent experiments. Synergistic interactions were confirmed by three independent experiments. According to the original study by Chou and Talalay, CI <1, = 1; and >1 indicate synergistic, additive, and antagonistic, respectively. In this study, combination effect was thought to be synergistic when CI was less than 0.9
  2. NE Not examined